Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0265264 (
HOS
)
1,119
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Overexpression of
KDM2B
is frequently occurred in various human solid tumours, and the high levels of
KDM2B
are associated with tumourigenesis. However, whether and how its activities might be modulated to facilitate tumour progression is still unclear. Immunoprecipitation and immunoblotting were carried out to detect the acetylation of
KDM2B
. Nucleosomes and mononucleosomes were prepared and the demethylation activity of
KDM2B
was detected in these two substrates. The effects of
KDM2B
acetylation on the transcription of target genes, as well as tumour growth and metastasis were then studied.
KDM2B
was acetylated in osteosarcoma cancer cell lines (MG-63 and
HOS
). This modification occurred at lysine 758 and catalysed by Tip60. Acetylation of
KDM2B
decreased the capacity of
KDM2B
in binding with nucleosomes.
KDM2B
acetylation diminished its demethylation activity towards nucleosomal substrates rather than towards bulk histone. Besides, acetylation of
KDM2B
diminished its ability to bind with the promoters of p21 and puma. Moreover, the promoting effects of
KDM2B
acetylation on tumour cells' proliferation and metastasis, and in vivo tumour growth were dependent on Tip60.
KDM2B
is acetylated at lysine 758 by Tip60 in human osteosarcoma cells. Acetylation of
KDM2B
diminishes its association with nucleosomes, and thus increasing methylation of H3K36 at its target genes as well as enhancing its oncogenic effects.
...
PMID:Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis. 3121 31
